Sign In

Login

Password

Forgot Password ? Sign Up

Zytokin-Freisetzungssyndrom (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Zytokin-Freisetzungssyndrom" in German language version.

refsWebsite
Global rank German rank
12doi.org
2nd place
3rd place
10nih.gov
4th place
7th place
3zdb-katalog.de
123rd place
6th place
1uab.edu
low place
low place
1aerztliche-anzeigen.de
low place
low place
1iiarjournals.org
low place
low place
1cancer.gov
1,684th place
7,111th place
1mdnxs.com
low place
low place
1roche.com
low place
6,801st place

aerztliche-anzeigen.de

cancer.gov

doi.org

  • D. W. Lee, R. Gardner, D. L. Porter, C. U. Louis, N. Ahmed, M. Jensen, S. A. Grupp, C. L. Mackall: Current concepts in the diagnosis and management of cytokine release syndrome. In: Blood, Band 124, Nr. 2, Juli 2014, S. 188–195, doi:10.1182/blood-2014-05-552729, PMID 24876563, PMC 4093680 (freier Volltext).
  • C. A. Barker, S. K. Kim, S. Budhu, K. Matsoukas, A. F. Daniyan, S. P. D’Angelo: Cytokine release syndrome after radiation therapy: case report and review of the literature. In: Journal for immunotherapy of cancer, Band 6, Nr. 1, Januar 2018, S. 1, doi:10.1186/s40425-017-0311-9, PMID 29298730, PMC 5795275 (freier Volltext).
  • S. L. Maude, D. Barrett u. a.: Managing cytokine release syndrome associated with novel T cell-engaging therapies. In: Cancer journal. Band 20, Nummer 2, 2014 Mar-Apr, S. 119–122, doi:10.1097/PPO.0000000000000035, PMID 24667956, PMC 4119809 (freier Volltext) (Review).
  • Lucette Doessegger, Maria Longauer Banholzer: Clinical development methodology for infusion-related reactions with monoclonal antibodies. In: Clinical & Translational Immunology. Band 4, Nr. 7, 2015, ISSN 2050-0068, S. e39, doi:10.1038/cti.2015.14, PMID 26246897, PMC 4524952 (freier Volltext).
  • Maurien D. Rombouts, Eleonora L. Swart, Alfons J. M. VAN DEN Eertwegh, Mirjam Crul: Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment. In: Anticancer Research. Band 40, Nr. 3, 2020, ISSN 1791-7530, S. 1201–1218, doi:10.21873/anticanres.14062, PMID 32132017 (iiarjournals.org).
  • Meletios A Dimopoulos et al.: Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. In: The Lancet Oncology. Band 22, Nr. 6, 2021, ISSN 1470-2045, S. 801–812, doi:10.1016/S1470-2045(21)00128-5.
  • H. S. Kulkarni, P. M. Kasi: Rituximab and cytokine release syndrome. In: Case reports in oncology, Band 5, Nr. 1, Januar 2012, S. 134–141, doi:10.1159/000337577, PMID 22666201, PMC 3364040 (freier Volltext)
  • L. C. Lim, L. P. Koh, P. Tan: Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. In: Journal of clinical oncology: official journal of the American Society of Clinical Oncology, Band 17, Nr. 6, Juni 1999, S. 1962–1963, doi:10.1200/jco.1999.17.6.1962, PMID 10561242.
  • S. Cooley, F. He u. a.: First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. In: Blood Advances, Band 3, Nummer 13, Juli 2019, S. 1970–1980, doi:10.1182/bloodadvances.2018028332, PMID 31266741, PMC 6616260 (freier Volltext).
  • N. V. Frey, D. L. Porter: Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. In: Hematology. American Society of Hematology. Education Program. Band 2016, Nummer 1, Dezember 2016, S. 567–572, doi:10.1182/asheducation-2016.1.567, PMID 27913530, PMC 6142489 (freier Volltext) (Review).
  • S. Breslin: Cytokine-release syndrome: overview and nursing implications. In: Clinical journal of oncology nursing, Band 11, Nr. 1 Suppl, Februar 2007, S. 37–42, doi:10.1188/07.CJON.S1.37-42, PMID 17471824 (Review).
  • Carl H. June, Michel Sadelain: Chimeric Antigen Receptor Therapy. In: New England Journal of Medicine, 2018, Band 379, Ausgabe 1 vom 5. Juli 2018, S, 64–73, doi:10.1056/NEJMra1706169

iiarjournals.org

ar.iiarjournals.org

mdnxs.com

nih.gov

ncbi.nlm.nih.gov

  • D. W. Lee, R. Gardner, D. L. Porter, C. U. Louis, N. Ahmed, M. Jensen, S. A. Grupp, C. L. Mackall: Current concepts in the diagnosis and management of cytokine release syndrome. In: Blood, Band 124, Nr. 2, Juli 2014, S. 188–195, doi:10.1182/blood-2014-05-552729, PMID 24876563, PMC 4093680 (freier Volltext).
  • C. A. Barker, S. K. Kim, S. Budhu, K. Matsoukas, A. F. Daniyan, S. P. D’Angelo: Cytokine release syndrome after radiation therapy: case report and review of the literature. In: Journal for immunotherapy of cancer, Band 6, Nr. 1, Januar 2018, S. 1, doi:10.1186/s40425-017-0311-9, PMID 29298730, PMC 5795275 (freier Volltext).
  • S. L. Maude, D. Barrett u. a.: Managing cytokine release syndrome associated with novel T cell-engaging therapies. In: Cancer journal. Band 20, Nummer 2, 2014 Mar-Apr, S. 119–122, doi:10.1097/PPO.0000000000000035, PMID 24667956, PMC 4119809 (freier Volltext) (Review).
  • Lucette Doessegger, Maria Longauer Banholzer: Clinical development methodology for infusion-related reactions with monoclonal antibodies. In: Clinical & Translational Immunology. Band 4, Nr. 7, 2015, ISSN 2050-0068, S. e39, doi:10.1038/cti.2015.14, PMID 26246897, PMC 4524952 (freier Volltext).
  • Maurien D. Rombouts, Eleonora L. Swart, Alfons J. M. VAN DEN Eertwegh, Mirjam Crul: Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment. In: Anticancer Research. Band 40, Nr. 3, 2020, ISSN 1791-7530, S. 1201–1218, doi:10.21873/anticanres.14062, PMID 32132017 (iiarjournals.org).
  • H. S. Kulkarni, P. M. Kasi: Rituximab and cytokine release syndrome. In: Case reports in oncology, Band 5, Nr. 1, Januar 2012, S. 134–141, doi:10.1159/000337577, PMID 22666201, PMC 3364040 (freier Volltext)
  • L. C. Lim, L. P. Koh, P. Tan: Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. In: Journal of clinical oncology: official journal of the American Society of Clinical Oncology, Band 17, Nr. 6, Juni 1999, S. 1962–1963, doi:10.1200/jco.1999.17.6.1962, PMID 10561242.
  • S. Cooley, F. He u. a.: First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. In: Blood Advances, Band 3, Nummer 13, Juli 2019, S. 1970–1980, doi:10.1182/bloodadvances.2018028332, PMID 31266741, PMC 6616260 (freier Volltext).
  • N. V. Frey, D. L. Porter: Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. In: Hematology. American Society of Hematology. Education Program. Band 2016, Nummer 1, Dezember 2016, S. 567–572, doi:10.1182/asheducation-2016.1.567, PMID 27913530, PMC 6142489 (freier Volltext) (Review).
  • S. Breslin: Cytokine-release syndrome: overview and nursing implications. In: Clinical journal of oncology nursing, Band 11, Nr. 1 Suppl, Februar 2007, S. 37–42, doi:10.1188/07.CJON.S1.37-42, PMID 17471824 (Review).

roche.com

uab.edu

zdb-katalog.de

  • Lucette Doessegger, Maria Longauer Banholzer: Clinical development methodology for infusion-related reactions with monoclonal antibodies. In: Clinical & Translational Immunology. Band 4, Nr. 7, 2015, ISSN 2050-0068, S. e39, doi:10.1038/cti.2015.14, PMID 26246897, PMC 4524952 (freier Volltext).
  • Maurien D. Rombouts, Eleonora L. Swart, Alfons J. M. VAN DEN Eertwegh, Mirjam Crul: Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment. In: Anticancer Research. Band 40, Nr. 3, 2020, ISSN 1791-7530, S. 1201–1218, doi:10.21873/anticanres.14062, PMID 32132017 (iiarjournals.org).
  • Meletios A Dimopoulos et al.: Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. In: The Lancet Oncology. Band 22, Nr. 6, 2021, ISSN 1470-2045, S. 801–812, doi:10.1016/S1470-2045(21)00128-5.